FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.0	C. 20549
-----------------	----------

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Ross Leonard S					EyePoint Pharmaceuticals, Inc. [EYPT]										eck all applic	ationship of Reporting all applicable) Director Officer (give title		g Person(s) to Issuer 10% Owner Other (specif		
	`	HARMACEUTIO	(Middle) CALS, IN	IC.		3. Date of Earliest Transaction (Month/Day/Year) 12/22/2018								_ 2	below)	See R	emar	below)		
(Street) WATER	ΓΟWN M		02472 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filed by One Form filed by One Person									Repo	n					
		Tab	le I - No	n-Deriv	ative	e Se	curit	ies Ac	quired	, Dis	sposed o	of, or	Ben	eficiall	y Owned					
Da			Date	2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securit Disposed				5) Securitie Benefici	eneficially wned Following		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(1	A) or D)	Price	Transaction(s) (Instr. 3 and 4)					
Common	Stock			12/22	/2018	3			М		62,89	2	A	(1)	94	,709	D D			
Common	Stock			12/22	/2018	3			F		18,522	(2)	D	\$1.65	³⁾ 76	,187				
		-	Table II -								osed of converti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transactio Code (Instr 8)		n of		6. Date E Expiration (Month/I	on Da		7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		s Security	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				C	Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title		Amount or Number of Shares	mber					
Restricted stock units	(1)	12/22/2018			M			62,892	(4)		(4)	Comr		62,892	\$0.00	0		D		

Explanation of Responses:

- 1. Restricted stock units convert into common stock on a one-for-one basis.
- 2. No shares were sold these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the
- 3. Reflects the last reported sale price for the Registrant's shares of common stock on the Nasdaq Global Market on December 21, 2018.
- 4. On December 22, 2017, the reporting person was granted 62,892 restricted stock units, vesting in full on the first anniversary of the grant date.

Vice President of Finance and Chief Accounting Officer

/s/ John Mercer, Attorney-in-

12/26/2018

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.